Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MQX-503 in Raynaud's Phenomenon
NCT00253331Phase 3Completed
- Sponsor
- MediQuest Therapeutics
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nitroglycerin in Raynaud phenomenon (3 arms), sponsored by MediQuest Therapeutics. Primary endpoint: Differential time for blood flow to return to baseline following cold exposure. Started Nov 2004; status: completed.
02
Drugs
nitroglycerin
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT00253331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253331.